Regulatory Strategy to Support Transformational Phase IIb/III
A small virtual oncology sponsor is gearing up to run a Transformational Phase IIb/III Trial in 2023. Indication- glioblastoma (GBM). Protocol amendment was submitted in Aug 2022, questions and discussions with FDA required. As of Dec 2022 the sponsor is focusing on closing a funding round, after which operations will ramp up. In addition to […]
READ MORE